Recently uncovered details about the immunoglobulin fraud scandal suggest that the implicated businessman did not import the drugs into Sri Lanka but instead produced them in his own facility. The latest audit report has brought to light another startling revelation: the businessman allegedly utilized machinery typically used for manufacturing fruit drinks to produce these critical medicines.
Previously, doubts were raised regarding Sri Lanka’s capability to manufacture complex drugs such as immunoglobulin, due to the intricate production processes involved. However, reports now indicate that the controversial businessman purportedly manufactured not only the immune globulin drug but also the cancer medication Rituximab in his factory. Concerns have been raised about the quality of these drugs, suggesting they may not meet required standards.